Immuno-oncology approaches have shown little efficacy against high-grade glioma, a devastating manifestation of brain cancer. A new study now finds a metabolic vulnerability in IDH1-mutant glioma that can be targeted to reprogram tumor-infiltrating macrophages and create a tumor microenvironment that is more responsive to immune-checkpoint therapy.
References
Yan, H. et al. N. Engl. J. Med. 360, 765–773 (2009).
Dang, L. et al. Nature 462, 739–744 (2009).
Chowdhury, R. et al. EMBO Rep. 12, 463–469 (2011).
Lu, C. et al. Nature 483, 474–478 (2012).
Klemm, F. et al. Cell 181, 1643–1660.e1617 (2020).
Kohanbash, G. et al. J. Clin. Invest. 127, 1425–1437 (2017).
Friedrich, M. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00201-z (2021).
Guo, X., Pan, Y. & Gutmann, D. H. Neuro-oncol. 21, 1250–1262 (2019).
Shinde, R. & McGaha, T. L. Trends Immunol. 39, 1005–1020 (2018).
Shinde, R. et al. Nat. Immunol. 19, 571–582 (2018).
McGaha, T. L. et al. Immunol. Rev. 249, 135–157 (2012).
Rothhammer, V. et al. Nature 557, 724–728 (2018).
Thackray, S. J., Mowat, C. G. & Chapman, S. K. Biochem. Soc. Trans. 36, 1120–1123 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Halaby, M.J., McGaha, T.L. 2-HG modulates glioma macrophages via Trp metabolism. Nat Cancer 2, 677–679 (2021). https://doi.org/10.1038/s43018-021-00231-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-021-00231-7
- Springer Nature America, Inc.
This article is cited by
-
Tumor-associated macrophage-related strategies for glioma immunotherapy
npj Precision Oncology (2023)